Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome characterised by significant emotional and physical symptoms, affecting many women globally. Emerging research indicates the potential of psychedelics, such as psilocybin and MDMA, in alleviating PMDD symptoms, highlighting a promising avenue for treatment.
What is Premenstrual Dysphoric Disorder (PMDD)?
PMDD is a severe and debilitating condition that affects approximately 3-8% of women in their reproductive years, often causing intense mood swings, irritability, anxiety, and physical symptoms such as breast tenderness and bloating.
The pathophysiology of PMDD is believed to involve complex interactions between hormonal fluctuations, neurochemical changes, particularly serotonin dysregulation, and genetic predispositions.
Symptoms typically begin in the luteal phase of the menstrual cycle and usually resolve with the onset of menstruation, severely impairing quality of life in affected individuals.
Current Treatments
Standard treatments include SSRIs (selective serotonin reuptake inhibitors), hormonal therapies, and lifestyle modifications, which can provide varying degrees of relief but may not be effective for all patients.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Premenstrual Dysphoric Disorder (PMDD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Clinical trials indicate significant mood improvement in patients with PMDD. | Medium | Moderate | Consistent |
| MDMA Research suggests MDMA may help alleviate emotional symptoms associated with PMDD. | Medium | Moderate | Consistent |
| Ketamine Some evidence suggests ketamine's fast-acting antidepressant effects may be applicable, but specific studies on PMDD are limited. | Small | Low | Inconsistent |
Psilocybin and Premenstrual Dysphoric Disorder (PMDD)
Psilocybin, a naturally occurring psychedelic compound, interacts predominantly with serotonin receptors, potentially addressing the serotonin dysregulation implicated in PMDD. Clinical studies have indicated that psilocybin can lead to significant reductions in anxiety and depressive symptoms, which are hallmark features of PMDD, thus enhancing emotional regulation and overall well-being during the menstrual cycle.
MDMA and Premenstrual Dysphoric Disorder (PMDD)
MDMA is known for its empathogenic effects and ability to create feelings of connection and emotional release. These traits may be particularly beneficial in managing the emotional volatility characteristic of PMDD. Research suggests that MDMA can help individuals process emotional trauma and reduce fear responses, which could alleviate the severity of PMDD-related mood disturbances.
Key Insights
- 1
Psilocybin has shown promise in reducing PMDD symptoms, with research indicating significant improvements in mood and emotional well-being.
- 2
A Phase 2 clinical trial focusing on psychedelic-assisted therapy for PMDD is currently underway, which could redefine treatment approaches.
- 3
Psychedelic microdosing has been explored as an alternative method to manage PMDD symptoms, with preliminary qualitative studies highlighting positive user experiences.
Industrial Landscape
Key players in this space include research institutions conducting clinical trials, patient advocacy groups focused on women's health, and pharmaceutical companies exploring psychedelic compounds for therapeutic use.
Quick Indicators
\"Ongoing clinical evaluations are investigating Premenstrual Dysphoric Disorder (PMDD) as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Premenstrual Dysphoric Disorder (PMDD).